Showing 5431-5440 of 9401 results for "".
- Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream for Atopic Dermatitishttps://practicaldermatology.com/news/secondary-efficacy-and-patient-reported-outcomes-in-phase-2b-clinical-trial-of-tapinarof-cream-for-atopic-dermatitis/2460435/Secondary efficacy and patient-reported outcomes from Dermavant's Phase 2b randomized clinical trial of tapinarof cream for the treatment of atopic dermatitis were recently reported in The Journal of the American Academy of Dermatology (JAAD). Tapinarof cream is a potential first-in-class, on
- Health Canada Approves Two New Gynecological Indications For Candela’s CO2RE Laser Platformhttps://practicaldermatology.com/news/health-canada-approves-two-new-gynecological-indications-for-candelas-co2re-laser-platform/2460434/Health Canada has approved Candela’s CO2RE laser for the treatment of genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI) in adult women. The CO2RE laser, a single CO2 platform equipped w
- Soliton’s Rapid Acoustic Pulse Device Improves Cellulite in Pivotal Studyhttps://practicaldermatology.com/news/solitons-rapid-acoustic-pulse-device-improves-cellulite-in-study/2460422/Patients treated with Soliton’s investigational Rapid Acoustic Pulse (RAP) device experienced an average 32.5 percent improvement in Cellulite Severity Score, according to newly released data presented via the American Academy of Dermatology (AAD) 2020 VMX Virtual Conference. The
- AAD Survey: Parents Get the Importance of Sunscreen for their Kidshttps://practicaldermatology.com/news/aad-survey-parents-get-the-importance-of-sunscreen-for-their-kids/2460433/Fully 74 percent of parents today worry about sun protection more with their children than their parents did with them, and 90 percent of parents believe it’s important to teach their children healthy habits now so they will keep them when they are adults, finds a new survey from the Americ
- New Phase 3 Data for Tremfya Show Consistent, High Levels of Skin Clearance Through Four Years in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-phase-3-data-for-tremfya-show-consistent-high-levels-of-skin-clearance-through-four-years-in-moderate-to-severe-plaque-psoriasis/2460431/New long-term plaque psoriasis data for The Janssen Pharmaceutical Companies of Johnson & Johnson's Tremfya (guselkumab) show consistent, high levels of skin clearance at week 100 and week 204 (four years). In the open-label extension of VOYAGE 2, at four years, 80 percent of pa
- Phase 3 Study Finds Twice-Weekly Enstilar Foam Safe and Effective for Long-Term Maintenance Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/phase-3-study-finds-twice-weekly-enstilar-foam-safe-and-effective-for-long-term-maintenance-treatment-of-plaque-psoriasis/2460427/LEO Pharma A/S presented results from the Phase 3 PSO-LONG clinical tria, which compared the efficacy and safety of twice-weekly Enstilar (calcipotriene and betamethasone dipropionate) Foam versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis.
- Further Evidence of Long-term Use and Cost-effectiveness of Ilumya for Psoriasis Presented at Virtual AADhttps://practicaldermatology.com/news/further-evidence-of-long-term-use-and-cost-effectiveness-of-ilumya-for-psoriasis-presented-at-virtual-aad/2460425/Sun Pharmaceutical Industries Ltd. presented further evidence of the long-term use and cost-effectiveness of tildrakizumab-asmn (Ilumya) in moderate to severe plaque psoriasis at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020. Long-term analyses of the reSURFA
- Late-Breaking Data: Skyrizi Achieves Superior Rates of Complete Skin Clearance for Psoriasis Compared to Secukinumab at 52 Weekshttps://practicaldermatology.com/news/late-breaking-data-show-skyrizi-achieves-superior-rates-of-complete-skin-clearance-for-psoriasis-compared-to-secukinumab-at-52-weeks/2460423/New late-breaking Phase 3b head-to-head data show superior rates of skin clearance for AbbVie's risankizumab-rzaa (Skyrizi) compared to secukinumab (Cosentyx) at week 52. Sixty-six percent of psoriasis patients receiving Skyrizi achieved completely clear skin—100 percent clearance in th
- Bimekizumab Phase 3 Data Show Superior Skin Clearance in Psoriasis vs. Placebo and Ustekinumabhttps://practicaldermatology.com/news/bimekizumab-phase-3-data-show-superior-skin-clearance-in-moderate-to-severe-psoriasis/2460421/UCB shared first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting. Patients treated with bimekizumab achieved superior
- Sciton Unveils mJOULE Platform Featuring BBL HERO And MOXIhttps://practicaldermatology.com/news/sciton-unveils-mjoule-platform-featuring-bbl-hero-and-moxi/2460420/Sciton Inc. is rolling out their mJOULE dual-wavelength platform which includes a new fractional treatment, MOXI, and BBL HERO. MOXI delivers non-ablative laser energy to revitalize skin and BroadBand Light HERO (High Energy Rapid Output) allows practitioners to treat the entire body wi